Novo Nordisk's (NVO) controlling shareholder, Novo Holdings, is looking to double the size of Catalent over five years as President-elect Donald Trump is likely to focus on US manufacturing, Reuters reported, citing an interview with a Novo Holdings senior partner.
Jonathan Levy said the company did not want to set a revenue target before agreeing on a corporate strategy with Catalent's management but noted that "doubling the size of your business over five years is always a nice barometer to work on," according to the report.
Levy said Catalent is set to hold its next board meeting in February, Reuters added.
Novo Holdings and Catalent did not immediately respond to MT Newswires' requests for comments.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.